3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
3
Urologic Diseases
2
Urinary Bladder Diseases
2
Carcinoma, Transitional Cell
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
91
Gemcitabine
55
Nivolumab
49
Cisplatin
38
atezolizumab
31
Carboplatin
30
avelumab
25
enfortumab vedotin
23
Docetaxel
23
Magnetic Resonance Spectroscopy
18
Ipilimumab
17
Paclitaxel
16
Mitomycin
15
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Transitional Cell
×
vofatamab
×
Clear all
NCT03123055
2020-03-18
FIERCE-22
Rainier Therapeutics
Phase 1/2
Terminated
28 enrolled
8 charts
NCT02401542
2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2
Terminated
71 enrolled
9 charts